0001415889-24-017899.txt : 20240624 0001415889-24-017899.hdr.sgml : 20240624 20240624090055 ACCESSION NUMBER: 0001415889-24-017899 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240613 FILED AS OF DATE: 20240624 DATE AS OF CHANGE: 20240624 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GARCIA PETER S CENTRAL INDEX KEY: 0001188956 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-39386 FILM NUMBER: 241062223 MAIL ADDRESS: STREET 1: ALX ONCOLOGY HOLDINGS INC. STREET 2: 866 MALCOLM ROAD, SUITE 100 CITY: BURLINGAME STATE: CA ZIP: 94010 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ALX ONCOLOGY HOLDINGS INC CENTRAL INDEX KEY: 0001810182 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 850642577 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 323 ALLERTON AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-466-7125 MAIL ADDRESS: STREET 1: 323 ALLERTON AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4/A 1 form4a-06242024_010651.xml X0508 4/A 2024-06-13 2024-06-17 0001810182 ALX ONCOLOGY HOLDINGS INC ALXO 0001188956 GARCIA PETER S C/O ALX ONCOLOGY HOLDINGS INC. 323 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 false true false false CHIEF FINANCIAL OFFICER 0 Common Stock 2024-06-13 4 P 0 12000 8.5282 A 122348 D For purposes of the short-swing profit recovery provisions of Section 16(b) of the Securities Exchange Act of 1934, the acquisition of shares reported herein may be deemed to be matchable to the extent of 1,893 shares with the reporting person's sale of 1,893 shares of Issuer common stock to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units on December 29, 2023. The reporting person has agreed to pay to the Issuer $11,959.88, which represents the full amount of the profit realized in connection with the short-swing transaction, less transaction costs. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.4113 to $8.68, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price. /s/ Peter Garcia 2024-06-24